Latest Safety News

Syrah Resources faces significant operational disruption at its Balama graphite mine due to ongoing protests, declaring force majeure while advancing its US-based Vidalia facility amid strong EV market growth.

IGO's December quarter report reveals robust performance at Greenbushes lithium mine but significant setbacks at Kwinana and Nova, culminating in a $79 million EBITDA loss and a strategic halt on Kwinana’s Plant 2.

NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.

Triangle Energy reports a solid cash position of $10.89 million as it prepares to drill the Becos-1 exploration well in early 2025, while managing ongoing transitions at the Cliff Head Oil Field and pursuing new ventures in the Philippines and UK.

Cynata Therapeutics reports encouraging Phase 1 results for its diabetic foot ulcer treatment CYP-006TK, alongside a strengthened balance sheet and ongoing clinical progress.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

Sandfire Resources reported a 5% increase in copper equivalent production for H1 FY25, alongside a reduction in injury rates and operating costs at its Motheo operation. The company secured key approvals for a new tailings facility at MATSA, underpinning long-term growth.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Biome Australia Limited has announced encouraging results from functional studies on its probiotic strain BMB18, highlighting its potential to modulate immune responses, reduce inflammation, and support intestinal health. These findings pave the way for targeted clinical research and product innovation.

Island Pharmaceuticals reports promising safety and anti-dengue activity in its Phase 2a trial of ISLA-101 and has commenced the Phase 2b therapeutic arm, backed by a fresh A$3.5 million capital raise.

Zimplats' December quarter report reveals a decline in mined and milled volumes alongside increased cash costs per 6E ounce, even as key expansion projects advance steadily.